Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
Our goal is to become a leader in rare respiratory disease therapeutics through the development and commercialization of novel, best-in-class medicines that address unmet medical needs in this field.